Abstract
The survival rate of patients with metastatic non-small-cell lung cancer remains poor even with chemotherapy. This randomised-controlled trial looks at the effect of monoclonal antibody against vascular endothelial growth factor (bevacizumab) in the treatment of patients with metastatic non-squamous-cell, non-small-cell-lung cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 259 |
| Number of pages | 1 |
| Journal | Thorax |
| Volume | 62 |
| Issue number | 3 |
| Publication status | Published - Mar 2007 |
| Externally published | Yes |
